Neuropathix
Doylestown, US · Founded 2013 · Delaware corporation
Neuropathix is a biopharmaceutical company developing patented cannabinoid-inspired molecules and therapeutics targeting inflammation for conditions including chemotherapy-induced peripheral neuropathy, hepatic encephalopathy, mild traumatic brain injury, and chronic pain. Its subsidiary Kannalife Sciences has licensed a U.S. government patent on cannabinoids as antioxidants and neuroprotectants, and its lead drug candidate KLS-13019 is a CBD-like new chemical entity.
Founders & leadership
DP
Dean PetkanasNamed on SEC filing
RM
ROBERT MALASEKNamed on SEC filing
Reported raises · per SEC filings
Form D private placements$1.3M disclosed across 2 of 4 rounds · 2017–2025
▶$50MofferedNov 2025 · BiotechnologyRule 506(c)
▶$50MofferedNov 2025 · Biotechnology
Rule 506(c)Officers, directors & promoters on the filing
- Dean PetkanasExecutive Officer, Director
- Offering amount
- $50M
- Minimum investment
- $100K
- Sales commissions
- $2.5M
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06c
▶$1.2MraisedFeb 2021 · 1 investors · PharmaceuticalsRule 506(b)
▶$1.2MraisedFeb 2021 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Dean PetkanasExecutive Officer, Director
- Robert MalasekDirector
- Timothy ScottDirector
- William KinneyExecutive Officer
- Blake SchroederDirector
- Thomas KikisExecutive Officer, Director
- Offering amount
- $1.2M
- Amount sold
- $1.2M
- First sale
- Feb 2021
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶$100KraisedJan 2020 · 1 investors · PharmaceuticalsRule 506(b)
▶$100KraisedJan 2020 · 1 investors · Pharmaceuticals
Rule 506(b)Officers, directors & promoters on the filing
- Robert MalasekDirector
- Mark CorraoExecutive Officer
- Thomas KikisExecutive Officer, Director
- Dead PetkanasExecutive Officer, Director, Promoter
- Blake SchroederDirector
- William KinneyExecutive Officer
- Offering amount
- $3M
- Amount sold
- $100K
- First sale
- Dec 2019
- Incorporated
- Corporation, Delaware
- Federal exemptions
- 06b
▶Undisclosed amountofferedSep 2017 · Other TechnologyRule 506(b)
▶Undisclosed amountofferedSep 2017 · Other Technology
Rule 506(b)Officers, directors & promoters on the filing
- ROBERT MALASEKExecutive Officer, Director
- Minimum investment
- $5K
- Incorporated
- Corporation, Delaware, 2013
- Federal exemptions
- 06b
Source: SEC EDGAR Form D. Amounts as filed; amended filings shown once at their latest values.
Competitors · 3
by search overlapNeurona Therapeutics6 shared keywordsNeurona is a clinical-stage biotherapeutics company developing allogeneic, off-the-shelf regenerative neural cell therapies that integrate into neural circuits to treat chronic neurological disorders. Its pipeline includes neuronal, glial, and gene-edited cell therapy candidates led by NRTX-1001, an inhibitory neuron therapy for epilepsy.</parameter>
<parameter name="founders">[]
Neuraptive6 shared keywordsNeuraptive is a biotechnology company staffed by professionals with expertise in research and development, manufacturing, and commercialization in the pharmaceutical industry.
Doximity5 shared keywordsDoximity is the largest verified network of healthcare professionals in the U.S., connecting physicians, PAs, NPs, pharmacists, and medical students across specialties and care settings. The platform provides mobile-first tools for clinical communication, collaboration, and workflow optimization.
Companies competing with Neuropathix for the same Google search keywords, organic and paid, via search-intersection analysis.
In the news
Frequently asked questions
- What does Neuropathix do?
- Neuropathix is a biopharmaceutical company developing patented cannabinoid-inspired molecules and therapeutics targeting inflammation for conditions including chemotherapy-induced peripheral neuropathy, hepatic encephalopathy, mild traumatic brain injury, and chronic pain. Its subsidiary Kannalife Sciences has licensed a U.S. government patent on cannabinoids as antioxidants and neuroprotectants, and its lead drug candidate KLS-13019 is a CBD-like new chemical entity.
- How much funding has Neuropathix raised?
- Neuropathix has disclosed $1.3M raised across 2 of its 4 known rounds.
- Where is Neuropathix headquartered?
- Neuropathix is headquartered in Doylestown, US.